Aden Ka-Yin Chan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2001173/publications.pdf

Version: 2024-02-01

31 papers	1,223 citations	393982 19 h-index	414034 32 g-index
32 all docs	32 docs citations	32 times ranked	2294 citing authors

#	Article	IF	Citations
1	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. Frontiers in Oncology, 2022, 12, 839302.	1.3	3
2	Lowâ€grade BRAF V600E mutant oligodendrogliomaâ€like tumors of children may show EGFR and MET amplification. Brain Pathology, 2021, 31, 211-214.	2.1	2
3	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Modern Pathology, 2021, 34, 1245-1260.	2.9	21
4	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. Clinical Neurology and Neurosurgery, 2021, 208, 106882.	0.6	1
5	Establishment and characterization of meningioma patient-derived organoid. Journal of Clinical Neuroscience, 2021, 94, 192-199.	0.8	9
6	STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. Molecular Cancer, 2021, 20, 147.	7.9	13
7	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathology, 2020, 30, 541-553.	2.1	73
8	Clinical and mutational profiles of adult medulloblastoma groups. Acta Neuropathologica Communications, 2020, 8, 191.	2.4	30
9	FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene, 2019, 38, 33-46.	2.6	41
10	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro-Oncology Advances, 2019, 1, vdz015.	0.4	22
11	SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. Oncogene, 2018, 37, 1159-1174.	2.6	36
12	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. Journal of Neuro-Oncology, 2018, 139, 307-322.	1.4	2
13	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. Laboratory Investigation, 2018, 98, 968-976.	1.7	33
14	Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathologica, 2018, 136, 641-655.	3.9	36
15	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. Laboratory Investigation, 2017, 97, 946-961.	1.7	24
16	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro-Oncology, 2017, 19, 1008-1010.	0.6	12
17	Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology, 2017, 19, 1327-1337.	0.6	177
18	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroupsâ€"A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology, 2017, 120, 1-9.	2.0	44

#	Article	IF	Citations
19	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	0.8	232
20	HG-07ABERRANTLY EXPRESSED microRNAs IN BRAF MUTATED YOUNG ADULT GBM. Neuro-Oncology, 2016, 18, iii49.2-iii49.	0.6	1
21	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget, 2016, 7, 64615-64630.	0.8	22
22	TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. New England Journal of Medicine, 2016, 375, 2206-2208.	13.9	16
23	Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget, 2016, 7, 5030-5041.	0.8	45
24	Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget, 2015, 6, 20885-20901.	0.8	42
25	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Modern Pathology, 2015, 28, 177-186.	2.9	107
26	TERTpromoter mutations contribute toIDHmutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget, 2015, 6, 24871-24883.	0.8	34
27	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. International Journal of Clinical and Experimental Pathology, 2015, 8, 11485-94.	0.5	11
28	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Modern Pathology, 2014, 27, 332-342.	2.9	45
29	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. International Journal of Clinical and Experimental Pathology, 2014, 7, 8627-36.	0.5	24
30	<scp>MIR</scp>â€137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets <scp>CSE1L</scp>. Brain Pathology, 2013, 23, 426-439.	2.1	39
31	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. PLoS ONE, 2013, 8, e67421.	1.1	25